IL-6 Inhibitor Compounds Targeting gp130 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and inflammatory diseases lack effective and specific inhibitors for the IL-6/gp130 signaling pathway, which is crucial in various pathological conditions, including cancer, due to the limited availability and potency of existing small molecule inhibitors.
Innovation Solution
Development of novel compounds, such as those represented by Formulas (A), (B), (C), (D), and (E), which target the IL-6/gp130 interaction to inhibit IL-6 signaling, potentially offering higher potency and specificity as anti-cancer and anti-inflammatory agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing small molecule inhibitors are used to target IL-6/gp130 signaling, then treatment options are available, but the potency and specificity are insufficient
Solution Approach 1:
The patent employs parameter changes by systematically modifying chemical structures (Formulas A-E with various substituents R1-R6) to optimize binding affinity and specificity to gp130, thereby improving inhibitor potency while maintaining structural diversity for effective treatment options
Solution Approach 2:
The patent develops composite chemical structures combining multiple functional groups and moieties in specific arrangements (as shown in Formulas A-E) to create inhibitors with enhanced potency and specificity for IL-6/gp130 signaling pathway blockade
2Object-affected harmful factors
If IL-6 signaling is inhibited to treat cancer and inflammatory diseases, then pathological conditions are addressed, but the dual nature of IL-6 (protective vs. harmful) creates treatment complexity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features ( particular substituent patterns in Formulas A-E) that target gp130 with high specificity, enabling selective blockade of pathological IL-6 signaling while potentially sparing protective functions through localized structural interactions
Solution Approach 2:
The patent uses small molecule inhibitors as intermediary compounds that bind to gp130 to prevent IL-6 from activating the signaling pathway, thereby mediating the blockade of harmful IL-6 effects while allowing the natural IL-6 system to remain intact for potential protective functions
Data Source
AI summary
The instant disclosure describes compounds having IL-6 modulating activity, pharmaceutical compositions and kits thereof, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.